Animalcare Ltd has launched Marbocare (marbofloxacin) 100mg/ml solution for injection, a third-generation fluoroquinolone for the treatment of E.coli mastitis and bovine respiratory disease (BRD) in cattle, and Metritis Mastitis Agalactia in pigs.Animalcare Ltd has launched Marbocare (marbofloxacin) 100mg/ml solution for injection, a third-generation fluoroquinolone for the treatment of E.coli mastitis and bovine respiratory disease (BRD) in cattle, and Metritis Mastitis Agalactia in pigs.

The company highlights the product's unique flexible dosage regimen of once daily injections for 3 days against E.coli mastitis and  BRD, plus a single intramuscular (IM) high dose (8mg/100kg) for BRD.

Animalcare says this regimen, coupled with the flexibility of administration afforded by all three injection routes (intravenous IV, subcutaneous SC and IM), a low volume dose and good syringeability, all combine to offer ease of use; resulting in a reduction in handling and less stress for the cattle.

Developed for veterinary use only, Marbocare has broad spectrum activity against Gram+ve and Gram-ve pathogens. Animalcare says the product is especially effective against E.coli mastitis and the key bacterial pathogens associated with BRD, as well as M.bovis.  

Marbocare has milk withdrawal times of 36 hours after the last treatment following the 3 day course and 72 hours after a single shot for BRD. Meat withdrawal is 6 days after multiple injections and 3 days after the single shot.

Marbofloxacin has proven efficacy in a comparative international, multi-centre, controlled, randomised field trial1 in 62 dairy cows with E.coli mastitis. Marbofloxacin cure rates were significantly higher than the control product. In respiratory disease it showed a more rapid clinical response in comparison to tilmicosin2, ceftiofur3 and oxytetracycline4. Marbofloxacin was shown to be well tolerated, leading to a fast return to appetite, liveweight gain and associated welfare benefits.

Marbocare is also licensed in the treatment of Metritis Mastitis Agalactia syndrome in pigs, given by IM injection, with a 4 day meat withdrawal.

Tony Liepman, Product Manager from Animalcare said: "Marbocare is competitively priced whether used on its own or alongside a single-dose anti-inflammatory such as Emdocam (meloxicam)."

Marbocare is a POM-V licensed product presented in 50 and 100ml multi-dose vials.

References

  1. Grandemange E. et al., Field evaluation of the efficacy of marbofloxacin in the treatment of acute mastitis due to Gram-ve bacteria in the dairy cow, Cattle Practice (2002), Issue 10, Part 1, 57-62.
  • Thomas E et al., A field comparison of the efficacy and tolerance of marbofloxacin in the treatment of BRD.JVet Pharmacol.Therapy (2001),24,353-358
  • Eyett-Burton C., Marbofloxacin: An advanced fluoroquinolone for use in beef and dairy cattle.Cattle Practice BCVA (1997),5,4
  • Thomas E et al Field evaluation of efficacy of a new antimicrobial, marbofloxacin in the treatment of BRD, Proceedings of the XIX World Buiatrics Congress Edinburgh (1996),54-57

PS: Whilst you're here, take a moment to see our latest job opportunities for vets.